Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年1月12日
	新闻
	The Targeted Pulse: Looking Back at 2024's Achievements and Exploring Potential ... Targeted Oncology In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. 标记为不相关
	Advancing lung cancer treatment through personalized medicine in the pharmaceutical industry Times of India Lung cancer is among the common types of cancer that affect many individuals and are associated with increased mortality rates due to rapid ... 标记为不相关
	Factors Associated With Suicide Among Patients With Lung Cancer in the United States - Cureus Cureus Among 843,750 lung cancer patients included in this study, suicide was the cause of death in 1,014 (0.12%) patients. The overall mean survival in ... 标记为不相关
	Horace Frederick "Bud" Richey, 86 - LkldNow LkldNow Bud courageously fought lung cancer and COPD for over 12 years. He was born in Dayton, OH on February 8th, 1938, and was the son of Horace Vernon ... 标记为不相关
	Spain becomes world leader in medical research - this is what it achieved in 2024 The Olive Press Patient Janusz Racz receives an injection of a BioNTech mRNA cancer immunotherapy for non-small cell lung cancer (NSCLC) - known as BNT116 - from ... 标记为不相关
	Two Prolia Biosimilars, One for Xolair Are in the Offing, Says AscellaHealth Report Managed Healthcare Executive Lung Cancer · Mental Health · Multiple Sclerosis · NSCLC · Neonatal Care · Obstetrics-Gynecology & Women's Health · Oncology · Opioids · PTSD · Pain. 标记为不相关
	This day in history | Local News Stories | wahpetondailynews.com This day in history | Local News Stories | wahpetondailynews.com ... Americas · Particulates · Luther Terry · Cancer · Tobacco Control · Cigarette · Lung Cancer · Smoking And Health. CONTACT US: (701) 642-8585 · Today's ... 标记为不相关
	Test of 'poisoned dataset' shows vulnerability of LLMs to medical misinformation Medical Xpress Lung cancer trial reveals 40% drop in deaths using biomarker testing. Jan 10, 2025. Let us know if there is a problem with our content. Use this form ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈